Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Effect of the application of trial inclusion criteria on the efficacy of adalimumab therapy in a rheumatoid arthritis cohort.

Visman IM, Bartelds GM, Ouwerkerk W, Ravelli AC, Peelen LM, Dijkmans BA, Boers M, Nurmohamed MT.

J Rheumatol. 2011 Sep;38(9):1884-90. doi: 10.3899/jrheum.101283. Epub 2011 Jun 15.

PMID:
21677005
2.

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ.

JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.

PMID:
21486979
3.

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ.

Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209.

4.

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.

Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, Crusius JB, Dijkmans BA, Tak PP, Aarden L, Wolbink GJ.

Arthritis Res Ther. 2010;12(6):R221. doi: 10.1186/ar3208. Epub 2010 Dec 27.

5.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
6.

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.

Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ.

Arthritis Res Ther. 2010;12(5):217. doi: 10.1186/ar3147. Epub 2010 Oct 20. Review.

7.

Therapy: Immunogenicity of biologic therapies-we need tolerance.

Krieckaert CL, Bartelds GM, Wolbink GJ.

Nat Rev Rheumatol. 2010 Oct;6(10):558-9. doi: 10.1038/nrrheum.2010.153. No abstract available.

PMID:
20882023
8.

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.

van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D.

J Immunol Methods. 2010 Oct 31;362(1-2):82-8. doi: 10.1016/j.jim.2010.09.005. Epub 2010 Sep 9.

PMID:
20833178
9.

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Wolbink GJ, de Vries N, Tak PP, Dijkmans BA, Crusius JB, van der Horst-Bruinsma IE.

Arthritis Rheum. 2009 Aug;60(8):2541-2. doi: 10.1002/art.24709. No abstract available.

10.

A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.

van den Bemt BJ, Vos K, den Broeder AA, Blom M, Thurlings RM, Bartelds GM, Stapel SO, Barrera P, Tak PP, Nurmohamed MT, Wolbink GJ.

Ann Rheum Dis. 2009 Aug;68(8):1368-9. doi: 10.1136/ard.2008.095448. No abstract available.

PMID:
19605744
11.

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 May;69(5):817-21. doi: 10.1136/ard.2009.112847. Epub 2009 Jul 5.

PMID:
19581278
12.

Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.

Hoving JL, Bartelds GM, Sluiter JK, Sadiraj K, Groot I, Lems WF, Dijkmans BA, Wijbrandts CA, Tak PP, Nurmohamed MT, Voskuyl AE, Frings-Dresen MH.

Scand J Rheumatol. 2009;38(4):246-50. doi: 10.1080/03009740902748264.

PMID:
19337948
13.

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.

Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.

J Rheumatol. 2008 Oct;35(10):1972-7. Epub 2008 Sep 1.

PMID:
18785316
14.

Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.

Bos WH, Bartelds GM, Vis M, van der Horst AR, Wolbink GJ, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Lems WF, Nurmohamed MT, Aarden L, Hamann D.

Ann Rheum Dis. 2009 Apr;68(4):558-63. doi: 10.1136/ard.2008.088401. Epub 2008 Apr 29.

PMID:
18445623
15.

The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.

Bos WH, Ursum J, de Vries N, Bartelds GM, Wolbink GJ, Nurmohamed MT, van der Horst-Bruinsma IE, van de Stadt RJ, Crusius JB, Tak PP, Dijkmans BA, van Schaardenburg D.

Ann Rheum Dis. 2008 Sep;67(9):1347-50. doi: 10.1136/ard.2008.089953. Epub 2008 Apr 3.

PMID:
18388157
16.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2007 Jul;66(7):921-6. Epub 2007 Feb 14.

17.

High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment.

Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BA, Nurmohamed MT.

Ann Rheum Dis. 2006 Sep;65(9):1249-50. No abstract available.

Supplemental Content

Loading ...
Support Center